Clinical trials: Malignant Melanomas
Metastatic Malignant Melanoma and Renal Cell Carcinoma
Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Partially HLA-matched irradiated donor lymphcyte infusion alone resulted in 27% overall response rate (ORR) in advanced renal cell carcinoma without significant toxicities.
- Trial name
- NCT01925118
- Testing
- Irradiated donor lymphocyte infusion
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Malignant Melanoma
A Study of Vemurafenib in Participants With Metastatic Melanoma
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer [AJCC])…
- Trial name
- NCT01307397
- Testing
- Vemurafenib
- Where
- 280 sites in Albania, Argentina and 42 more
- Volunteers
- 3,219 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma
GM-CSF as Adjuvant Therapy of Melanoma
This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in…
- Trial name
- NCT00350597
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Northern California Melanoma Center
Skin Cancer
An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
The purpose of this study is to determine whether a skin cancer prevention website is effective at reduce female teenagers' desire to use indoor tanning and ultimately their use of indoor tanning over an 18 month period.
- Trial name
- iSTART (NCT01508013)
- Testing
- Appearance-Focused Website Intervention, Control Website
- Where
- United States
- Volunteers
- 443 people, healthy volunteers welcome
- Sponsor
- East Tennessee State University
Melanoma, Lung Cancer
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03050047
- Testing
- BCD-100
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Melanoma, Skin
DermaSensor Postmarket Surveillance Study
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
- Trial name
- NCT06666790
- Testing
- Scan with elastic scattering spectroscopy device to assess risk of malignancy
- Where
- 2 sites in United States
- Volunteers
- 396 people
- Sponsor
- DermaSensor, Inc.
Unresectable Melanoma, Metastatic Melanoma
Sargramostim (GM-CSF) + PD-1
This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT04703426
- Testing
- Sargramostim (GM-CSF), Pembrolizumab (anti-PD-1)
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
- Trial name
- NCT01515189
- Testing
- Ipilimumab
- Where
- 88 sites in United States, Argentina and 20 more
- Volunteers
- 831 people
- Sponsor
- Bristol-Myers Squibb
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Melanoma, Melanoma Stage III
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
- Conditions
- Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
- Trial name
- NCT06771544
- Testing
- Pembrolizumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, Irvine
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Advanced Melanoma
Study of Temzolomide and Gleevec in Advanced Melanoma
This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients…
- Trial name
- NCT00667953
- Testing
- Gleevec, Temodar
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications
The goal of this study is to evaluate the genomic profiles and investigate the prevalence of germ line and pathogenic mutations in Greek population with early and metastatic melanoma and their correlation with the treatment and…
- Trial name
- NCT05119829
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- Hellenic Cooperative Oncology Group
Melanoma
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.
- Trial name
- THERAVAC (NCT01331915)
- Testing
- Theravac
- Where
- Belgium
- Volunteers
- 23 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metastatic Melanoma
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
This open-label phase II trial studies how well niraparib works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
- Trial name
- NCT03925350
- Testing
- Niraparib
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- California Pacific Medical Center Research Institute
Metastatic Melanoma
The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Melanoma is the main cause of death in patients with skin cancer. Once it has metastasized, this cancer has been shown to respond to chemotherapy only in rare cases.
- Trial name
- NCT00279058
- Testing
- Immunotherapy treatment for melanoma
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Hadassah Medical Organization
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma
- Trial name
- NCT04544748
- Testing
- GNR-051
- Where
- 12 sites in Russia
- Volunteers
- 48 people
- Sponsor
- AO GENERIUM
Melanoma (Skin)
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00755976
- Testing
- epirubicin hydrochloride, sulindac, immunologic technique
- Where
- 10 sites in Ireland
- Volunteers
- 32 people
- Sponsor
- Cancer Trials Ireland
Melanoma, Cancer
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.
- Trial name
- PREMIUM (NCT05097378)
- Testing
- Encorafenib + Binimetinib, Standard Adjuvant Treatment
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- CCTU- Cancer Theme
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.